English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the present report we used oligonucleotide microarray analysis for the identification of genes characterizing the late-stage metastatic phenotype of malignant melanoma. A panel of 5,600 genes was analysed in a low aggressive and a highly aggressive (metastatic) human malignant melanoma cell line, respectively. More than 300 differentially regulated genes were identified. High metastatic potential correlated with upregulated mRNA expression in the groups of cytoskeletal proteins, apoptosis and cell cycle proteins, GTP binding proteins and oncogenes, extracellular ligands and receptors, transcription and translation factors. In contrast, most angiogenesis factors, extracellular matrix molecules, and melanoma-specific antigens were downregulated. Particular target genes were further analysed by in situ hybridization and immunohistochemical staining of primary malignant melanomas and melanoma metastases. Here, we show that thrombospondin 2, an extracellular matrix molecule which was differentially regulated in the microarray analysis, was strongly expressed in melanoma metastases, but not in primary tumours. The identification of thrombospondin 2 as a target molecule emphasizes the importance of cell-matrix interactions for the pathogenesis of malignant melanoma metastasis and may open future perspectives for treatment of this tumour.

Differential Expression of Thrombospondin 2 in Primary and Metastatic Malignant Melanoma